Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Key Points

• Vanda reported Q results of ($0.82) EPS, missing the consensus of ($0.69) by $0.13 and showing a negative return on equity (23.85%) and a net margin of -102.02%.
• Insiders have been net sellers recently — 314,342 shares were sold in the last three months (about $2.58M), with corporate insiders now owning 8.90% of the stock.
• The stock traded at $7.44 (+0.7%) with a market cap of $447.4M, while analysts hold a consensus rating of “Moderate Buy” and an average price target of $14.90.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.13), Zacks reports. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.

Vanda Pharmaceuticals Stock Up 0.7%

VNDA traded up $0.05 on Wednesday, hitting $7.44. The company had a trading volume of 1,667,480 shares, compared to its average volume of 2,208,623. The stock has a fifty day moving average price of $7.62 and a 200-day moving average price of $6.77. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $9.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.38 and a current ratio of 2.39. The stock has a market capitalization of $447.37 million, a price-to-earnings ratio of -1.99 and a beta of 0.65.

Insider Buying and Selling

In other news, CMO Joakim Wijkstrom sold 30,800 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $8.27, for a total transaction of $254,716.00. Following the sale, the chief marketing officer owned 333,469 shares in the company, valued at approximately $2,757,788.63. The trade was a 8.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Gunther Birznieks sold 42,431 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,904.37. Following the sale, the senior vice president owned 494,197 shares in the company, valued at $4,087,009.19. The trade was a 7.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 314,342 shares of company stock valued at $2,583,985 over the last three months. Corporate insiders own 8.90% of the company's stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently modified their holdings of the business. Martingale Asset Management L P grew its stake in shares of Vanda Pharmaceuticals by 87.3% during the fourth quarter. Martingale Asset Management L P now owns 33,114 shares of the biopharmaceutical company's stock worth $292,000 after acquiring an additional 15,431 shares during the last quarter. PharVision Advisers LLC purchased a new stake in shares of Vanda Pharmaceuticals during the third quarter worth about $285,000. Royal Bank of Canada grew its stake in shares of Vanda Pharmaceuticals by 34.3% during the first quarter. Royal Bank of Canada now owns 55,713 shares of the biopharmaceutical company's stock worth $256,000 after acquiring an additional 14,232 shares during the last quarter. Graham Capital Management L.P. purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth about $203,000. Finally, Algert Global LLC acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth about $174,000. Hedge funds and other institutional investors own 88.14% of the company's stock.

Analysts Set New Price Targets

VNDA has been the topic of several research reports. Zacks Research lowered Vanda Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 18th. HC Wainwright raised their price target on Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Monday, February 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research note on Monday, April 20th. Truist Financial assumed coverage on Vanda Pharmaceuticals in a research note on Thursday, March 5th. They set a "buy" rating and a $18.00 price target on the stock. Finally, Wall Street Zen lowered Vanda Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, February 14th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $14.90.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company's research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda's mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda's flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.